Aesthetic Plastic Surgery

, Volume 36, Issue 1, pp 140–148 | Cite as

Prophylactic Mastectomy: Is It Worth It?

  • Jose Abel de la Peña-Salcedo
  • Miguel Angel Soto-Miranda
  • Jose Fernando Lopez-Salguero



Breast cancer is the second mortality-related cancer and the leading cause of general mortality in women aged 40–55. Prophylactic mastectomy has proved to be effective in several clinical scenarios but is still a somewhat controversial procedure.


We performed a retrospective study by reviewing the records of all patients who underwent prophylactic mastectomy in a 25-year period. We evaluated the aesthetic and long-term oncologic outcomes, complications, and patient satisfaction.


We had 52 patients, 40 of them unilateral cases (contralateral prophylactic mastectomy) and 12 bilateral (bilateral prophylactic mastectomy) for a total of 64 mastectomized breasts. We had 1 (1.56%) case of unexpected breast cancer in the mastectomy specimens. Forty-two (65.62%) cases had a subcutaneous prophylactic mastectomy and 22 (34.37%) cases had a simple total prophylactic mastectomy. Fifty-eight (90.62%) cases underwent reconstruction with alloplastics and 6 (9.37) cases with autologous tissue of which 5 (7.81%) cases received latissimus dorsi flaps with alloplastic implants and 1 (1.56%) case had a TRAM flap. The complications included 4 (6.25%) breasts that developed capsular contracture, 2 (3.12%) cases of hematoma, and 1 (1.56%) infection. Concerning patient satisfaction, 39 (75%) patients reported being highly satisfied, 10 (19.23%) partially satisfied, and 3 (5.76%) unsatisfied. When we performed the aesthetic evaluation according to our scale, we got an overall aesthetic index of 8.8.


Prophylactic mastectomy is becoming an increasingly frequent procedure. Plastic surgeons should consider the aesthetic outcome when planning mastectomy and reconstruction. Our ability to predict the high-risk population has improved and it is that population who can get the best benefit from this intervention. The recommendation against subcutaneous prophylactic mastectomy lacks scientific evidence. There is plenty of evidence that prophylactic mastectomy lowers the risk of breast cancer in the high-risk population in at least 95%. Our experience with prophylactic mastectomy is extremely satisfactory, with an overall patient satisfaction rate of 94%, no mortality, and an oncologic long-term outcome of 0% of ulterior development of breast cancer. Our series, although relatively small, should provide some insight into the power of this technique and we think all plastic surgeons should have it in their surgical armamentarium and should share their experiences so that this procedure may become more widely accepted. We also think that plastic surgeons should strive for perfecting the technique to reduce the complication rate and therefore help the procedure gain acceptance by the medical community.


Prophylactic mastectomy Subcutaneous mastectomy Breast 



The authors declare that they have no conflicts of interest to disclose.


  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33PubMedCrossRefGoogle Scholar
  2. 2.
    Ries LAG, Kosary CL, Hankey BF et al (eds) (1999) SEER cancer statistics review, 1973–1996. National Cancer Institute, BethesdaGoogle Scholar
  3. 3.
    Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055–1062PubMedCrossRefGoogle Scholar
  4. 4.
    Herrington LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286CrossRefGoogle Scholar
  5. 5.
    Armes JE, Trute L, White D et al (1999) Distinct molecular pathogenesis of early onset breast cancer in BRCA1 and BRCA2 mutations carriers: a population-based study. Cancer Res 59:2011–2017PubMedGoogle Scholar
  6. 6.
    Offit K, Brown K (1994) Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 12:1724–1736PubMedGoogle Scholar
  7. 7.
    Osin P, Crook T, Powles T, Peto J, Gusterson B (1998) Hormone status of in situ cancer in BRCA1 and BRCA2 mutations carriers. Lancet 351:1487PubMedCrossRefGoogle Scholar
  8. 8.
    Pennisi VR, Capozzi A (1989) Subcutaneous mastectomy data: final statistics analysis. Aesthetic Plast Surg 13:15–21PubMedCrossRefGoogle Scholar
  9. 9.
    Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decisions analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465–1471PubMedCrossRefGoogle Scholar
  10. 10.
    Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T (1993) The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:892–897PubMedCrossRefGoogle Scholar
  11. 11.
    Armstrong K, Eisen A, Weber B (2000) Assessing the risk of breast cancer. N Engl J Med 342:564–571PubMedCrossRefGoogle Scholar
  12. 12.
    Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRefGoogle Scholar
  13. 13.
    Spear SL, Schwarz KA, Venturi ML, Barbosa T, Al-Attar A (2008) Prophylactic mastectomy and reconstruction: clinical outcomes and patient satisfaction. Plast Reconstr Surg 122(1):1–9PubMedCrossRefGoogle Scholar
  14. 14.
    Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1 positive or BRCA2 positive patients. J Clin Oncol 16:979–985PubMedGoogle Scholar
  15. 15.
    Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman K, Neugut AI (1999) Benefits and cost of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 17:495–500Google Scholar
  16. 16.
    Hartmann LC, Schaid DJ, Woods JE, Grotty JP, Myers JL, Arnold PG (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84PubMedCrossRefGoogle Scholar
  17. 17.
    Hamm RM, Lawler F, Scheid D (1999) Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med 340:1837–1838PubMedCrossRefGoogle Scholar
  18. 18.
    Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439–445PubMedCrossRefGoogle Scholar
  19. 19.
    McDonnell SK, Schaid DJ, Myers JL et al (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMedGoogle Scholar
  20. 20.
    Van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA (2002) Decision analysis of prophylactic surgery or screening for BRCA mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 20:2092–2100PubMedCrossRefGoogle Scholar
  21. 21.
    Frost MH, Schaid DJ, Sellers TA et al (2000) Long term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319–324PubMedCrossRefGoogle Scholar
  22. 22.
    Spear SL, Carter ME, Schwarz D (2005) Prophylactic mastectomy: indications, options, and reconstructive alternatives. Plast Reconstr Surg 115(3):891–909PubMedCrossRefGoogle Scholar
  23. 23.
    Gabriel SE, Woods JE, O’Fallon WM et al (1997) Complications leading to surgery after breast implantation. N Engl J Med 336:667–682CrossRefGoogle Scholar
  24. 24.
    Spear SL, Majidian A (1998) Immediate breast reconstruction in two stages using textured, integrated-valve tissue expanders, breast implants: a retrospective review of 171 consecutive breast reconstructions from 1989 to 1996. Plast Reconstr Surg 101(1):53–63PubMedCrossRefGoogle Scholar
  25. 25.
    Moore TS, Farrel LD (1992) Latissimus dorsi myocutaneous flap for breast reconstruction: long-term results. Plast Reconstr Surg 89(4):666–672PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and International Society of Aesthetic Plastic Surgery 2011

Authors and Affiliations

  • Jose Abel de la Peña-Salcedo
    • 1
  • Miguel Angel Soto-Miranda
    • 1
  • Jose Fernando Lopez-Salguero
    • 1
  1. 1.Institute for Plastic SurgeryHuixquilucanMexico

Personalised recommendations